Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma-Reference-Cited by-同舟云学术

Acute exacerbation of asthma induced by combined therapy of programmed death-1 Blocker plus lenvatinib in a patient with advanced hepatocellular carcinoma

Published:2021-10 Issue: Volume:156 Page:122-124
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Wang Huaiyuan^ORCID,Shi Jie,Wang Xuezhu,Zhao Haitao,Wang Hanping^ORCID

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference10 articles.

1. Immune checkpoint inhibitors in hepatocellular carcinoma: opportunities and challenges;Liu;Oncol,2019

2. Immune-related adverse events: a case-based approach;Connolly;Front Oncol,2019

3. Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer;Cho;Lung Canc,2018

4. Tumor-infiltrating lymphocyte-mediated pleuritis followed by marked shrinkage of metastatic kidney cancer of the chest wall during nivolumab treatment;Yanagihara;Ann Oncol,2017

5. Asthma exacerbations: pathogenesis, prevention, and treatment;Castillo;J Allergy Clin Immunol Pract,2017

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ipilimumab Induced Tracheobronchitis – An Under-Recognized Manifestation of Immune-Related Adverse Events;Journal of Medical Clinical Case Reports;2024-02-19

2. Sarcoidosis and Airway Disease After Immune Checkpoint Inhibitor Therapy: Case Study and Review of the Literature;Journal of Immunotherapy and Precision Oncology;2023-03-21

3. Airway disorders associated with immune checkpoint inhibitor therapy: Two case reports and a systematic review;Seminars in Oncology;2022-12

4. Fractional exhaled nitric oxide in checkpoint inhibitor pneumonitis: a case report and literature review;Immunotherapy;2022-12

5. Biological and immunosuppressive therapies for lung disease: a potential reciprocal influence between their use and malignancy;Lung Diseases and Cancer;2022-11